NASDAQ:DRTS Alpha Tau Medical (DRTS) Stock Price, News & Analysis $2.68 -0.19 (-6.62%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.72 +0.03 (+1.31%) As of 02/21/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Alpha Tau Medical Stock (NASDAQ:DRTS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alpha Tau Medical alerts:Sign Up Key Stats Today's Range$2.65▼$2.9750-Day Range$2.68▼$4.2052-Week Range$1.75▼$4.39Volume51,278 shsAverage Volume120,682 shsMarket Capitalization$187.39 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company OverviewAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Read More… Alpha Tau Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreDRTS MarketRank™: Alpha Tau Medical scored higher than 58% of companies evaluated by MarketBeat, and ranked 433rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAlpha Tau Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlpha Tau Medical has received no research coverage in the past 90 days.Read more about Alpha Tau Medical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Alpha Tau Medical are expected to decrease in the coming year, from ($0.45) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alpha Tau Medical is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alpha Tau Medical is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlpha Tau Medical has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.20% of the float of Alpha Tau Medical has been sold short.Short Interest Ratio / Days to CoverAlpha Tau Medical has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alpha Tau Medical has recently decreased by 21.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlpha Tau Medical does not currently pay a dividend.Dividend GrowthAlpha Tau Medical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.20% of the float of Alpha Tau Medical has been sold short.Short Interest Ratio / Days to CoverAlpha Tau Medical has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alpha Tau Medical has recently decreased by 21.62%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News SentimentN/A News SentimentAlpha Tau Medical has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Alpha Tau Medical this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Alpha Tau Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alpha Tau Medical insiders have not sold or bought any company stock.Percentage Held by Insiders39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.65% of the stock of Alpha Tau Medical is held by institutions.Read more about Alpha Tau Medical's insider trading history. Receive DRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address DRTS Stock News HeadlinesAlpha Tau announces FDA approval of IDE supplementFebruary 3, 2025 | msn.comAlpha Tau DaRT Shows Promising Interim Data In Cancer Trials, Shares RiseJanuary 29, 2025 | nasdaq.comElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.February 22, 2025 | True Market Insiders (Ad)Alpha Tau announces interim data from pembrolizumab combination trialJanuary 28, 2025 | markets.businessinsider.comAlpha Tau receives IDE from FDA for study evaluating Alpha DaRT, chemo comboJanuary 27, 2025 | markets.businessinsider.comAlpha Tau shares interim data across multiple clinical trials at R&D Update DayJanuary 27, 2025 | markets.businessinsider.comDRTS Stock Soars to 52-Week High, Reaching $4.12 Amid Healthcare SurgeJanuary 27, 2025 | msn.comAlpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update DayJanuary 27, 2025 | globenewswire.comSee More Headlines DRTS Stock Analysis - Frequently Asked Questions How have DRTS shares performed this year? Alpha Tau Medical's stock was trading at $3.10 on January 1st, 2025. Since then, DRTS shares have decreased by 13.5% and is now trading at $2.68. View the best growth stocks for 2025 here. How were Alpha Tau Medical's earnings last quarter? Alpha Tau Medical Ltd. (NASDAQ:DRTS) issued its quarterly earnings data on Monday, May, 20th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. Who are Alpha Tau Medical's major shareholders? Top institutional shareholders of Alpha Tau Medical include Levin Capital Strategies L.P. (0.45%), Northern Trust Corp (0.07%) and Renaissance Technologies LLC (0.06%). How do I buy shares of Alpha Tau Medical? Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alpha Tau Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alpha Tau Medical investors own include Datadog (DDOG), Advanced Micro Devices (AMD), Broadcom (AVGO), Meta Platforms (META), PayPal (PYPL), Sunrun (RUN) and ZIM Integrated Shipping Services (ZIM). Company Calendar Last Earnings5/20/2024Today2/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:DRTS CUSIPN/A CIK1871321 Webhealthcarecapitalcorp.com Phone972-3577-4115FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$9.00 Low Stock Price Target$7.00 Potential Upside/Downside+196.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.62% Return on Assets-29.89% Debt Debt-to-Equity Ratio0.08 Current Ratio10.99 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book2.23Miscellaneous Outstanding Shares69,920,000Free Float42,304,000Market Cap$188.78 million OptionableNo Data Beta0.83 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:DRTS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpha Tau Medical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alpha Tau Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.